医学
酒精性肝病
脂肪性肝炎
益生菌
食品药品监督管理局
疾病
肝硬化
肝病
脂肪肝
肠道菌群
临床试验
脂肪变性
重症监护医学
生物信息学
内科学
药理学
免疫学
生物
细菌
遗传学
作者
Fengyuan Li,Kangmin Duan,Cuiling Wang,Craig J. McClain,Wenke Feng
摘要
Despite extensive research, alcohol remains one of the most common causes of liver disease in the United States. Alcoholic liver disease (ALD) encompasses a broad spectrum of disorders, including steatosis, steatohepatitis, and cirrhosis. Although many agents and approaches have been tested in patients with ALD and in animals with experimental ALD in the past, there is still no FDA (Food and Drug Administration) approved therapy for any stage of ALD. With the increasing recognition of the importance of gut microbiota in the onset and development of a variety of diseases, the potential use of probiotics in ALD is receiving increasing investigative and clinical attention. In this review, we summarize recent studies on probiotic intervention in the prevention and treatment of ALD in experimental animal models and patients. Potential mechanisms underlying the probiotic function are also discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI